119-hres396

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 396 Introduced in House

    (IH) ]

<DOC>

119th CONGRESS
 1st Session
H. RES. 396

 Expressing support for the designation of the week of May 4, 2025, 
 through May 10, 2025, as ``Tardive Dyskinesia Awareness Week''.

_______________________________________________________________________

 IN THE HOUSE OF REPRESENTATIVES

 May 7, 2025

 Mr. Peters (for himself, Mr. Bilirakis, Mr. Mullin, and Mr. Bean of 
Florida) submitted the following resolution; which was referred to the 
 Committee on Energy and Commerce

_______________________________________________________________________

 RESOLUTION

 Expressing support for the designation of the week of May 4, 2025, 
 through May 10, 2025, as ``Tardive Dyskinesia Awareness Week''.

Whereas many people living with serious mental illnesses (for example, bipolar 
 disorder, major depressive disorder, schizophrenia, and schizoaffective 
 disorder) or gastrointestinal disorders (for example, gastroparesis, 
 upset stomach, nausea, and vomiting) may be treated with medications 
 that work as dopamine receptor blocking agents, including antipsychotics 
 and antiemetics;
Whereas, while ongoing treatment with these medications can be necessary, 
 prolonged use may be associated with tardive dyskinesia

    (TD) , an 
 involuntary movement disorder that is characterized by uncontrollable, 
 abnormal, and repetitive movements of the face, torso, limbs, and 
 fingers or toes;
Whereas even mild symptoms of TD can impact people physically, socially, and 
 emotionally;
Whereas it is estimated that TD affects approximately 600,000 people in the 
 United States, and approximately 65 percent of people with TD have not 
 been diagnosed, making it important to raise awareness about the 
 symptoms;
Whereas it is important that people taking these medications be monitored for TD 
 by a health care provider, and regular screening for TD is recommended 
 by the American Psychiatric Association;
Whereas clinical research has led to approval of treatments for adults with TD 
 by the Food and Drug Administration, and recognition and treatment of TD 
 can make a positive impact in the lives of many people experiencing 
 psychotic and mood disorders; and
Whereas the House of Representatives can raise awareness of TD among the public 
 and medical community: Now, therefore, be it
 Resolved, That the House of Representatives--

    (1) expresses support for the designation of ``Tardive 
 Dyskinesia Awareness Week''; and

    (2) encourages each individual in the United States to 
 become better informed about and aware of tardive dyskinesia.
 <all>